Combination treatment for HER2-positive stomach cancer that spread to the liver
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of treatments for stomach cancer that has spread to the liver. It combines a procedure that blocks blood flow to the liver tumor (TACE), heat/cold ablation to destroy it, and medications (chemotherapy, an antibody-drug conjugate, and an immunotherapy) to fight the cancer throughout the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old.
- Have stomach cancer that has spread to the liver, confirmed by biopsy.
- Have tumors that show high levels of the HER2 protein (IHC 2+ or 3+).
- Haven't had prior treatment with antibody-drug conjugates (like targeted chemo) or immunotherapy (like PD-1 blockers).
- Be well enough to be up and about (ECOG score 0–1) and have a life expectancy of at least 3 months.
- Have not had recent local liver treatments (within 28 days) and have at least one measurable tumor (≥10mm on CT scan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a combination of three drugs — an immunotherapy (sintilimab), a targeted therapy (bevacizumab), and chemotherapy — for a specific type of stomach cancer that produces high AFP and has spread to the liver. The goal is to see if this treatment can shrink tumors enough to make them removable by surgery.
This study tests a combination of drugs (including an investigational drug called KN026) for people with HER2-positive stomach cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatment.
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
This trial tests a new combination of two drugs for stomach cancer that has spread and shows a specific protein (HER2). The goal is to see if the combination helps patients who haven't had treatment for advanced disease.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
Hear when a new Gastric Cancer With Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.